Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital NHS foundation trust, Denmark Hill, London, UK.
Acta Ophthalmol. 2011 Aug;89(5):405-11. doi: 10.1111/j.1755-3768.2010.02079.x. Epub 2011 Feb 5.
Proliferative diabetic retinopathy (PDR) is the most common cause of severe visual loss in people with diabetes. Although panretinal photocoagulation (PRP) remains the gold standard of care to date, several combinations of new treatment modalities have emerged. These approaches can be used to increase the extent of treatment, expedite the effect of laser treatment and provide alternate measures when laser delivery is difficult or impossible, especially in patients with vitreous haemorrhage. Currently, most of the research in this field is focussed on inhibitors of vascular endothelial growth factor (VEGF), referred to herein as anti-VEGF agents. Although limited by their short-lived effects and a lack of established protocols, anti-VEGF agents are widely available, especially for the treatment of aggressive PDR. This review analyses published studies using anti-VEGF agents alone or as an adjunct to other therapies in the treatment of PDR.
增生型糖尿病视网膜病变（PDR）是糖尿病患者视力严重丧失的最常见原因。虽然全视网膜光凝（PRP）仍然是迄今为止的金标准治疗方法，但已经出现了几种新的治疗方式的组合。这些方法可以用于增加治疗范围，加速激光治疗效果，并在激光治疗困难或不可能时提供替代措施，特别是在玻璃体积血的患者中。目前，该领域的大部分研究都集中在血管内皮生长因子（VEGF）抑制剂上，以下简称抗 VEGF 药物。尽管抗 VEGF 药物的作用持续时间短且缺乏既定方案，但它们的应用仍然非常广泛，特别是用于治疗侵袭性 PDR。本综述分析了使用抗 VEGF 药物单独或作为其他治疗方法的辅助手段治疗 PDR 的已发表研究。
